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doi:10.101Polymorphisms in Genes That Regulate Cyclosporine
Metabolism Affect Cyclosporine Blood Levels and
Clinical Outcomes in Patients Who Receive Allogeneic
Hematopoietic Stem Cell Transplantation
Youngil Koh,1 Inho Kim,1,2,3 Dong-Yeop Shin,1 Ji-Yeon Bae,2 Hyun-Kyung Kim,4
Sung-Soo Yoon,1,2 Sung Sup Park,4 Dong Soon Lee,4 Seonyang Park,1,2,3 Byung Kook Kim1,2In patients who received allogeneic hematopoietic stem cell transplantation (HSCT), we investigated the cor-
relations between single nucleotide polymorphisms (SNPs) in genes that regulate cyclosporine metabolism
and clinical outcomes. All patients received sibling-matched HSCT. DNA samples of patients and donors
were analyzed for 4 SNPs: MDR1 11236C.T (rs1128503), 12677G.T.A (rs2032582), 13435C.T
(rs1045642), and CYP3A5 16986G.A (rs776746). A total of 156 patients (median age 40 years) were an-
alyzed. Nineteen patients received HSCT for nonmalignant disease. The CYP3A5 16986AA genotype was
associated with a high cyclosporine blood level after transplantation. However, this genotype was not related
to any particular clinical outcome. In contrast, the MDR111236C.T SNP was correlated with specific clin-
ical outcomes. When neither the donor nor the recipient had the CC genotype of MDR1 11236, patients
had lower creatinine levels (P\.001) and less transplantation-related mortality (TRM) (P5 .012). These pa-
tients also showed longer overall survival (OS) in both univariate (P5 .003) and multivariate (P5 .003) anal-
yses. Although the CYP3A5 16986AA genotype was correlated with a high blood cyclosporine
concentration, lack of the MDR1 11236CC genotype in both the donor and recipient was correlated
with less TRM and a longer OS in patients who received allogeneic HSCT.
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Cyclosporine is 1 of the most commonly used im-
munosuppressants in transplantation medicine and is
used in kidney [1], liver [2], and hematopoietic stem
cell transplantations (HSCTs). Cyclosporine is exten-
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6/j.bbmt.2011.08.019(CYP3A) subfamily of enzymes, with\1% of the ad-
ministrated dose excreted as unaltered cyclosporine
[3]. At the cellular level, cyclosporine is effluxed
by the P-glycoprotein, the protein product of the
MDR1 gene. P-glycoprotein, particularly in the small
intestine, limits the absorption of cyclosporine by the
active extrusion of cyclosporine from an enterocyte
back into the gut lumen [4]. In addition, CYP3A and
MDR1 in liver and biliary canaliculi can accelerate
the secretion of the drug into the bile and are largely
responsible for the drug clearance of cyclosporine sys-
temically [5].
Thus, theoretically, the blood level of cyclospor-
ine is at least partly determined by the functional ac-
tivity of CYP3A and P-glycoprotein. There are
genetic polymorphisms known to affect the functional
activity of CYP3A and P-glycoprotein [6,7]. Several
studies have investigated the association between
these polymorphisms and the blood level of cyclo-
sporine in renal transplantation [7-9]. It is well
known that the blood level of cyclosporine is an
important measurement in renal transplantation
because cyclosporine daily doses must be adjusted37
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order to improve the efficacy and reduce the toxicity of
cyclosporine treatment [8].
Of the CYP3A family genes, CYP3A4 is the domi-
nant enzyme and CYP3A5 the second most important
in the human liver and small intestine [10]. To date,
a number of single nucleotide polymorphisms (SNPs)
in the CYP3A4 and CYP3A5 genes have been identified
and published on the Human Cytochrome P450
Allele Nomenclature Committee home page (http://
www.imm.ki.se/CYPalleles). Among these polymor-
phisms, only the CYP3A5 16986G.A (rs776746) is
present inmore than 5%of theAsian population. There
are also 3 SNPs in the MDR1 gene: 11236C.T
(rs1128503), 12677G.T.A (rs2032582), and
13435C.T (rs1045642) that are present in .5% of
the Asian population. These aforementioned SNPs
are known to be functional and correlate with expres-
sion of CYP3A5 [11] and MDR1 [12].
Unfortunately, in contrast to renal transplanta-
tion, few are available regarding the correlation be-
tween these SNPs and the clinical outcomes of
patients receiving allogeneic HSCT. In allogeneic
HSCT, cyclosporine toxicity appears to be dose re-
lated [13], and there is a correlation between cyclo-
sporine levels and clinical outcomes. In a study by
Yee et al. [14], development of acute graft-versus-
host disease (GVHD) was related to trough cyclospor-
ine blood level. However, researchers also believe that
there must be intricate interactions that control im-
mune responses other than mere cyclosporine blood
level that may affect development of GVHD or
transplantation-related mortality (TRM). It is possible
that SNPs in the MDR1 gene may affect clinical out-
comes in patients who received allogeneic HSCT
because the P-glycoprotein enhances the energy-
dependent cellular efflux of cyclosporine in entero-
cytes and other cells.
To summarize, previous studies regarding SNPs in
the CYP3A subfamily and MDR1 genes were per-
formed almost exclusively in renal transplant patients
and used a pharmacokinetic approach that focused pri-
marily on the cyclosporine blood level. However, the
clinical impact of these SNPs on allogeneic HSCT
has yet to be studied.
In this study, we tried to define the impact of the
aforementioned SNPs on allogeneic HSCT by eluci-
dating the correlations between these SNPs and cyclo-
sporine blood levels and clinical outcomes, including
TRM and GVHD, after allogeneic HSCT. Our as-
sumptions were as follows: (1) as CYP3A5 is related
to the metabolism of cyclosporine, an SNP in this
gene would affect the blood level of cyclosporine. (2)
SNPs in the MDR1 gene may be associated with
changes in clinical outcomes after allogeneic HSCT
because P-glycoprotein is related to the cellular efflux
of cyclosporine at the cellular level. Also, we performedgenotyping of CYP3A5 of the recipient and MDR1 of
both donor and recipient.Design and Methods
Study population
Adult ($15 years) patients who had received allo-
geneic HSCT between 2000 and 2010 and agreed to
donate blood samples for genetic testing were included
in this study. Data regarding patient demographics,
laboratory test profiles, TRM, and overall survival
(OS) were obtained by medical record review.
Patients were categorized into 3 classes (high-,
intermediate-, and low-risk groups) according to the
severity of their underlying disease. Diseases that led
to placement in the high-risk group included leuke-
mias, lymphomas, renal cell carcinoma, and myelodys-
plastic syndromes that were not in complete remission,
whereas a patient with leukemia or lymphoma in com-
plete remission was placed in the intermediate risk
group. Patients with nonmalignant diseases, such as
aplastic anemia or sickle cell anemia, were categorized
as low risk. Assessed clinical outcomes included the
baseline creatinine to peak creatinine ratio, the base-
line bilirubin to peak bilirubin ratio, the peak aspartate
aminotransferase, and alanine aminotransferase during
2 weeks after HSCT. The development of acute
GVHD (aGVHD), the TRM, and the OS duration
were also measured. OS was calculated from the time
of HSCT to death from any cause.
Conditioning regimen for allogeneicHSCT varied
according to the type of underlying disease and the
condition of the patient. For myeloablative HSCT,
combination of busulfan and cyclophosphamide was
mainly used for malignant disease, wheres combina-
tion of antithymocyte globulin and cyclophosphamide
(6fludarabine) was used for nonmalignant disease. For
nonmyeloablative HSCT, the combination of fludara-
bine andmelphalan was mainly used. The prophylactic
regimen against GVHD used at the Seoul National
University Hospital is composed of cyclosporine and
methotrexate. In myeloablative HSCT, cyclosporine
is administered through continuous intravenous infu-
sion at a dose of 5 mg/kg from day 22 to day 3. The
dose is then changed to 3 mg/kg (again administered
via continuous intravenous infusion) from day 3 to
day 14 [15]. In nonmyeloablative HSCT, cyclosporine
is administered through continuous intravenous infu-
sion at a dose of 3 mg/kg from day 21 to day 30 [16].
T cell depletion is not performed in either myeloabla-
tive or nonmyeloablativeHSCT. After the infusion pe-
riod, subsequent dose modification is based on blood
cyclosporine levels.
The study protocol was reviewed and approved by
the institutional review board of the Seoul National
University Hospital, and the recommendations of the
Table 1. Baseline Characteristics of 156 Patients Who
Received Allogeneic HSCT
Number of
Patients (%) Number
Age (median, range) 40.3 (16.1-71.0)
Gender
Male 90 (57.7)
Female 66 (42.3)
Stem cell source
Peripheral blood 76 (48.7)
Bone marrow 73 (46.8)
Both 7 (4.5)
Risk of underlying disease
Active malignancy* 87 (55.8)
Malignancy in CR 50 (32.1)
Benign disease 19 (12.2)
Conditioning method
Myeloablative 79 (50.6)
Nonmyeloablative 77 (49.4)
Cyclosporine blood level
(mean, range)
Day 1 (ng/dL) 471.6 (82-2200)
Day 3 (ng/dL) 445.6 (87-7120)
Day 7 (ng/dL) 326.7 (67-1364)
Day 30 (ng/dL) 300.3 (39-960)
Acute GVHD development
No 109 (69.9)
Grade 1 4 (2.6)
Grade 2 22 (14.1)
Grade 3 10 (6.4)
Grade 4 11 (7.1)
Creatinine elevation after HSCT
(>2-fold)
Yes 54 (34.6)
No 100 (64.1)
Unknown 2 (1.3)
Bilirubin elevation after HSCT
(>2-fold)
Yes 116(74.4)
No 38 (24.4)
Unknown 2 (1.3)
*Malignancy included acute leukemia, chronic leukemia, myelodysplastic
syndrome, non-Hodgkin lymphoma, multiple myeloma, and renal cell
carcinoma.
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Genotyping
The genotyping for the MDR1 polymorphisms
11236C.T (rs1128503) and 13435C.T (rs1045642)
and the CYP3A5 polymorphism 16986G.A
(rs776746) were performed using the TaqMan fluoro-
genic 50 nuclease assay (ABI, Foster City, CA). The fi-
nal volume of the polymerase chain reaction (PCR)was
5 mL and contained 10 ng of genomic DNA, 2.5 mL of
TaqMan Universal PCR Master Mix, and 0.13 mL of
40 Assay Mix (Assay ID C___7586662_10 for
rs1128503, C__7586657_20 for rs1045642, and
C__26201809_30 for rs776746). The thermal cycle
conditions were as follows: 50C for 2 minutes to acti-
vate the uracil N-glycosylase and prevent carryover
contamination, then 95C for 10 minutes to activate
the DNA polymerase, followed by 45 cycles of 95C
for 15 seconds and 60C for 1 minute. All PCRs were
performed using 384-well plates and a Dual 384-Well
GeneAmp PCR System 9700 (ABI), and the endpoint
fluorescent readings were performed with an ABI
PRISM 7900 HT Sequence Detection System (ABI).
Duplicate samples and negative controls were included
to ensure the accuracy of the genotyping.
The genotyping of the MDR1 polymorphism
12677G.T.A was performed via the SNaPshot
method. The SNaPshot assay was performed accord-
ing to the manufacturer’s instructions (ABI PRISM
SNaPShot Multiplex kit). Analysis was performed
with Genemapper software (version 4.0; Applied Bio-
systems, Bedford, MA). The primer set used for the
SNaPshot assay was as follows: Forward primer:
TTGTTGAAATGAAAATGTTGTCTG; Reverse
primer: AAAATAACACTGATTRGAATACTTTA
CTCTACT. The melting temperature used for this
assay was 55C.Statistical Analysis
Statistical analyses of 2  2 contingency tables of
categorical variables were performed using the Pear-
son’s chi-square test or the Fisher exact test, as appro-
priate. For parametric continuous variables, we
performed the Student t test or analysis of variance
(ANOVA) for comparisons. For nonparametric vari-
ables, the Kruskal-Wallis test was used. The median
durations of OS were calculated using the Kaplan-
Meier method, and comparisons between groups
were made with the log-rank test. The impact of con-
tinuous numeric variables on clinical outcomes was
calculated using logistic regression and a Cox regres-
sion model. Multivariate analysis was performed using
a logistic regression model for response and Cox re-
gression models for OS. All statistical tests were 2
sided, and significance was defined as P \ .05. Allanalysis was performed using the Statistical Package
for the Social Sciences for Windows Version 12.0
(IBM, Chicago, IL).RESULTS
Patient Characteristics
A total of 156 patients were included in this study.
The median age of the patients was 40.3 years (range:
16.1-71.0 years), and the male-to-female ratio was
90:66. Themost common underlying disease in the pa-
tients that led to allogeneic HSCT was acute myeloid
leukemia (n 5 53; 34.0%). Overall, 137 patients re-
ceived allogeneic HSCT for malignant disease.
Among the 137 patients, 50 patients were in complete
remission, whereas 87 patients were not. Seventy-
seven (49.4%) patients received nonmyeloablative
HSCT. The source of the stem cells used in the
HSCT was peripheral blood in 76 patients, bone mar-
row in 73 patients, and both in 7 patients. Fifty-four
Table 2. Allele and Genotype Frequencies of the MDR1 and CYP3A5 Genes in 156 Patients
SNP Allele Frequencies Genotype Frequencies
MDR1 +1236 C T CC CT TT
Donor 38.8% 61.2% 15.4% 44.9% 37.2%
Recipient 39.7% 60.3% 15.4% 46.2% 35.3%
MDR1 +2677 G T A GG GT GA TT AA TA
Donor 38.4% 40.8% 20.9% 17.3% 28.8% 10.9% 16.7% 6.4% 16.7%
Recipient 46.0% 36.2% 17.8% 21.2% 30.1% 15.4% 11.5% 1.3% 16.0%
MDR1 +3435 C T CC CT TT
Donor 60.5% 39.5% 34.0% 50.0% 13.5%
Recipient 64.8% 35.2% 40.4% 45.5% 11.5%
CYP3A5 +6986 G A GG GA AA
80.1% 19.9% 62.8% 29.5% 4.5%
Figure 1. Associations between the CYP3A5 16986 SNP and cyclo-
sporine blood levels at day 1 and day 3. The CYP3A5 16986AA geno-
type was associated with high cyclosporine blood levels at day 1 (A)
and day 3 (B).
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creatinine after HSCT. GVHD that was scored at
greater than grade 3 developed in 21 patients
(13.5%), and the TRM rate was 30.1%During median
follow-up time of 89.1 months, 99 patients died. The
median OS duration of the patients was 15.9 months.
The risk group a patient was placed in based on under-
lying disease was found to be strongly predictive of OS
duration in these patients (P\ .001), as being in the
high-risk group was inversely associated with survival.
These characteristics are summarized in Table 1.
Genotyping Results
Mutant allele and genotype frequencies are shown
in Table 2. The genotype frequencies were not signif-
icantly different from the Hardy-Weinberg equation.
A total of 36.5% (54 of 148) of the patients were in per-
fect linkage disequilibrium for the MDR1 13435 and
11236 genotypes. Although strong associations were
observed between MDR1 SNPs, perfect linkage dis-
equilibrium was not observed in .50% of patients.
Hence, the impact of individual SNPs on clinical out-
come and cyclosporine blood level was performed
without consideration of linkage disequilibrium. The
MDR1 genotype and the CYP3A5 genotype did not
show significant linkage disequilibrium.
Impact of Genotype Results on Cyclosporine
Blood Level
Cyclosporine blood levels were measured in 89,
132, 139, and 133 patients on day 1, day 3, day 7,
and day 30, respectively. The CYP3A5 16986 AA ge-
notype was associated with a high blood level of cyclo-
sporine at day 1 (P 5 .040) and was marginally
associated with an elevated cyclosporine blood level
at day 3 (P 5 .064) (Figure 1). However, there were
no significant associations found between aMDR1 ge-
notype and the cyclosporine blood level.
Impact of Genotype Results on Clinical
Outcome
The CYP3A5 16986 genotype did not have pre-
dictive value in terms of clinical outcomes. Therewas no predictive value in the MDR1 genotype of ei-
ther the stem cell donor or the recipient. However,
when theMDR1 genotypes of the donor and the recip-
ient were considered together, the MDR1 11236 ge-
notype was predictive of clinical outcomes.
When the MDR111236 genotype of both the do-
nor and the recipient were considered together, pa-
tients were able to be categorized into 3 groups: (1)
both the donor and the recipient possessed the CC ge-
notype (n 5 10), (2) both the donor and the recipient
possessed a non-CC genotype (n 5 104), and (3) the
Figure 2. Impact of the MDR111236 SNP on the clinical outcome of patients who received allogeneic HSCT.When both the donor and the recipient
did not possess the1267 CC genotype, patients experienced lower elevations in creatinine (A) and bilirubin (B), less TRM (C), and longer OS (D). *The
bar designates mean value. In panels (A) and (B), the values that exceeded the y-axis maximum are not shown.
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(n 5 33). When both the donor and the recipient did
not possess the CC genotype of MDR1 11236, pa-
tients displayed significantly lower elevations in alanine
aminotransferase (P 5 .022), aspartate aminotransfer-
ase (P 5 .036), creatinine (P \ .001), and bilirubin
(P 5 .034) after allogeneic HSCT than the other pa-
tients. This patient subset also experienced less TRM
(P 5 .012) and survived longer (P 5 .003) (Figure 2).
In multivariate analysis that considered a patient’s
age, risk group, stem cell source, conditioningmethod,
andMDR111236 genotype, theMDR111236 geno-
type was found to be an independent prognostic factor
for OS (P 5 .003) (Table 3). However, the MDR1
11236 genotype was not correlated with the develop-
ment of aGVHD (P 5 .201).DISCUSSION
In contrast to renal transplantation, little is known
about the impact of MDR1 and CYP3A subfamily
SNPs on allogeneic HSCT. Recently, Japanese re-
searchers have studied the impact of CYP3A5 and
MDR1 SNPs on neurotoxicity in patients receiving al-
logeneic HSCT. Although performed with a small
number of patients (n 5 30), the study indicated that
the MDR1 11236C.T polymorphism is important
in the development of neurotoxicity [17]. Likewise, al-
though Kim et al. [18] asserted that the MDR112677
SNP would have correlation with survival receiving al-
logeneic HSCT previously, the study focused only on
OS, which depends on multiple parameters. Hence,
the interpretation of the study result by Kim et al.[18] is dubious. We believe that, to specifically analyze
the clinical impact of MDR1 and CYP3A subfamily
SNPs on allogeneic HSCT, more precise study design
focusing on specific short-term events is necessary.
In our study, a CYP3A5 polymorphism was found
to be correlated with cyclosporine blood levels during
the first 3 days afterHCST.TheCYP3A516986G.A
SNPwas recently reported to be a frequently occurring
SNPwithin intron 3 of CYP3A5 and the primary cause
of polymorphism in the CYP3A5 protein [19]. The
presence of the CYP3A5 16986 AA genotype results
in a splicing defect leading to the absence of CYP3A5
activity [20]. This finding correlates well with our re-
sult that indicated high cyclosporine blood levels in pa-
tients with the CYP3A5 AA genotype. We believe that
the reason this polymorphism did not impact the day 7
and day 30 blood levels was because the attending phy-
sicians altered the dose of administered cyclosporine
based on the day 1 and day 3 blood levels. Also, al-
though there was a significant association between
the CYP3A5 16986 genotype and the blood level of
cyclosporine, the genotype of CYP3A5 did not affect
clinical outcome. This agrees with a previous study
that failed to demonstrate a direct correlation between
cyclosporine level and the occurrence of GVHD or
TRM [14]. By the way, although our results are theo-
retically justified, because the number of patients
who harbored the AA genotype was small, our results
should be interpreted cautiously and we believe that
further confirmatory testing is necessary.
The most interesting findings were in regard to the
MDR111236 polymorphism.The combination of the
donor and recipient not having the MDR111236 CC
Table 3. Hazard Ratio (HR) and P Value of Age, Stem Cell
Source, Conditioning Method, Risk of Underlying Disease, and
MDR1 +1236 Genotype for Death in Multivariate Analysis
Overall Survival
HR
95% Confidence Interval
Lower Upper P Value
Age 1.018 0.998 1.039 .077
Stem cell source .969
Peripheral blood 1
Bone marrow 1.021 0.563 1.849
Both 1.172 0.336 4.081
Conditioning method .573
Nonmyeloablative 1
Myeloablative 1.200 0.637 2.263
Risk of underlying disease .008
Nonmalignant disease 1
Malignancy in remission 2.357 0.784 7.089
Active malignancy 4.098 1.403 11.967
MDR1 +1236 genotype .003
CC (both) 1
Hetero 0.709 0.312 1.613
Non-CC (both) 0.367 0.171 0.789
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allogeneic HSCT. This association with a favorable
outcome was indicated with various clinical parame-
ters. However, theMDR111236C.Tpolymorphism
is known to be silent and is linked to the functional
SNPsMDR113435C.T andMDR112677G.T.A
[21], and the MDR1 13435TT genotype is known to
express lower levels of P-glycoprotein in peripheral
blood mononuclear cells [22] and duodenal cells [12].
Thus, our results indirectly suggest that the favorable
outcome associated with not having the MDR1
11236 CC genotype may be because of a low level of
cellular P-glycoprotein expression. Theoretically, low
P-glycoprotein expression would lead to high intracel-
lular cyclosporine concentration in target cells, includ-
ing white blood cells. We believe high intracellular
cyclosporine concentration is attributable to low
TRMand longOSobserved in our study patients.The-
oretically, one can postulate that not having theMDR1
11236 CC genotype should lessen the probability of
developing aGVHD. However, because not having
the MDR1 11236CC genotype did not have any sig-
nificant relationshipwith the development of aGVHD,
the underlying mechanism of these phenomena is not
clear, and further study is necessary.
We performed genotyping on both the donors and
the recipients for MDR1 SNPs because it was not cer-
tain if P-glycoprotein expression in the donor cells or
the recipient would be important for the clinical out-
come of the patients. Although neither the genotype
of the donor nor the recipient independently influ-
enced the clinical outcome of the patients, they had
strong predictive value when considered together.
We think this is because P-glycoprotein expression
in both the duodenum (which consists of recipientcells) and peripheral blood cells (which are from the
donor) is important for the clinical outcome.
As this study has the limitation of being a retrospec-
tive study, our results might be recognized by some as
exploratory data. However, our study was not small
(n 5 156), and the clinical impact of MDR1 11236
SNP was demonstrated via the measurement of multi-
ple parameters. Hence, we hypothesize that genotyp-
ing for these SNPs may have important clinical value
in the near future.
In conclusion, among patients receiving allogeneic
HSCT, theCYP3A516986AAgenotypewas associated
with a high blood cyclosporine concentration, whereas
the situation in which the donor and the patient did
not have the MDR1 11236 CC genotype was signifi-
cantly associated with less TRM and longer OS.ACKNOWLEDGMENTS
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